Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: How stem cells may help people with epilepsy
Is it normal to have a pet disease? Ever since I did a project on epilepsy in grade 4, I’ve had an interest in this disorder that affects one percent of the Canadian population, and worldwide there are anywhere from 50-65 million people living with epilepsy, depending on the source. (Every year, 15,500 Canadians learn […]
Right Turn: Heart attacks, stroke and regenerative medicine
The month of March recognizes World Day of the Fight Against Sexual Exploitation (March 4, find helpful information and resources), International Women’s Day (March 8) and Women’s History Month so there’s a lot of focus on women right now. It seems like a good time to talk about women’s health. Heart attacks and strokes happen […]
Right Turn: Science and art help us see coronavirus in novel way
A new science art show premiers today online and runs until April 30th, 2021. Radha Chaddha, a Toronto-based visual artist, and cell and molecular biologist, has created a virtual exhibit that explores the impacts of the COVID-19 pandemic as told through light and dance. With funding from the Government of Ontario, the piece is being […]
Right Turn: Patients need to educate themselves about regenerative medicine
The more attention stem cells, cell therapies and gene therapies get, the more education there needs to be so the public can differentiate between approved and unapproved treatments. At this time, there are over 1,220 clinical trials ongoing worldwide (including tissue engineered products). According to the Alliance for Regenerative Medicine[1], there are 152 Phase III […]